Linagliptin Does Not Increase Adverse Renal Events in Patients With T2D, Kidney Disease

Treatment with linagliptin in patients with type 2 diabetes and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events.

Source: Linagliptin Does Not Increase Adverse Renal Events in Patients With T2D, Kidney Disease – Endocrinology Advisor

About the Author

Stephanie Figon, MS, RDN, LD

Founder of NutriScape.NET. As a dietitian since 1992, Steph Figon has had experiences in consulting, 15 years in clinical, and has operated a private practice nutrition counseling office for since 2011. The RDNutriScape Instagram

Tags:

Related Posts